Rana McKay, MD, provides commentary and insight on a recent study that examined safety and radiation protection considerations for 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma. The abstract, “Radiation Protection Considerations With 89Zr-girentuximab PET/CT,” was presented at the 2024 Society of Nuclear Medicine and Molecular Imagining Annual Meeting.
Safety Considerations for 89Zr-girentuximab PET/CT Imaging in ccRCC
By Rana McKay, MD - Last Updated: June 25, 2024Related Posts
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
Dr. Dan Joyce discusses key SUO studies on RCC prognostics, personalized medicine, and advancements in treatment strategies.
Dr. Karam explains the main points of emphasis when it comes to small renal masses and surveillance versus surgery.
Serial ctDNA negativity or clearance was linked to improved PFS compared with persistent ctDNA positivity during treatment.
The phase 3 ZIRCON trial demonstrated positive results with use of the agent for patients with ccRCC.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.